Body mass index influences the response to infliximab in ankylosing spondylitis

Table 2 Baseline characteristics of the ankylosing spondylitis patients treated with infliximab according to the response BASDAI50 after 6 months of infliximab

	Yes (n= 77)^a	No (n= 62)^a	Pvalue
Age (years), median (IQR)	39.4 (32.0 -50.0)	44.8 (38.2-53.0)	0.0469
Gender (% males)	72.7	51.6	0.0102
Disease duration (years), median (IQR)	8.0 (4.0-14.0)	6.0 (3.0-12.0)	0.1966
BMI (kg/m²)	24.4 (21.9-26.8)	28.7 (25.6-31.6)	< 0.0001
HLAB27 (% of patients)	73.3	56.9	0.0470
Δweight (kg), median (IQR)	-1.0 (-2.0-2.0)	0.0 (-2.0-3.0)	0.4948
Baseline CRP (mg/dl), median (IQR)	14.0 (5.0-26.0)	6.6 (3.0-13.0)	0.0039

^aTwo patients withdrew from IFX therapy (lack of response and serious adverse event) and BASDAI50 lacking data for 14 AS patients
BASDAI50, 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range.

ISSN: 1478-6362